- Home
- NAUT
as 11-21-2024 4:00pm EST
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 284.7M | IPO Year: | N/A |
| Target Price: | $4.50 | AVG Volume (30 days): | 116.7K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $3.46 | Next Earning Date: | 10-29-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Nautilus Biotechnolgy Inc. (NAUT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Godwin Mary E. | NAUT | Senior VP, Operations | Sep 23 '24 | Sell | $2.87 | 47,031 | $134,743.82 | 0 | |
| Godwin Mary E. | NAUT | Senior VP, Operations | Sep 17 '24 | Sell | $2.85 | 35,000 | $99,869.00 | 0 |
Latest Nautilus Biotechnolgy Inc. News
NAUT Breaking Stock News: Dive into NAUT Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
3 US Penny Stocks With Market Caps Up To $400M
GlobeNewswire
21 days ago
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
GlobeNewswire
22 days ago
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
GuruFocus.com
23 days ago
Nautilus Biotechnology Inc (NAUT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
GlobeNewswire
23 days ago
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
Simply Wall St.
a month ago
We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth
GlobeNewswire
a month ago
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024
GlobeNewswire
2 months ago
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
Compare NAUT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAUT Nautilus Biotechnolgy Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.